Adding ivosidenib to oral azacitidine for AML with IDH1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a targeted pill (ivosidenib) to another maintenance drug (oral azacitidine) can help keep your leukemia in remission longer. It is for older adults with a specific gene change (IDH1) who have finished intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have a type of acute myeloid leukemia (AML) with an IDH1 mutation.
- You are in remission after intensive chemotherapy (not a stem cell transplant).
- You are not a candidate for a stem cell transplant.
- Your kidneys and liver are working well enough, and you are generally able to take oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.